{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:55:21Z","timestamp":1790798121046,"version":"4.1.0"},"reference-count":22,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:p>\n                    Irritable bowel syndrome (IBS) is a chronic relapsing gastrointestinal problem characterised by intestinal pain and associated alterations of defecation and\/or bowel habit (constipation: IBS-C or diarrhoea: IBS-D).\n                    <jats:sup>1,2<\/jats:sup>\n                    Opioid receptors in the gut have a role in gastrointestinal motility, secretion and sensation.\n                    <jats:sup>3<\/jats:sup>\n                    \u03a4 Eluxadoline (Truberzi-Allergan) is a locally acting, mixed opioid receptor agonist\/antagonist licensed for the treatment of IBS-D in adults.\n                    <jats:sup>4<\/jats:sup>\n                    Here, we consider the evidence for eluxadoline and how it fts with current management strategies for IBS-D.\n                  <\/jats:p>","DOI":"10.1136\/dtb.2017.8.0514","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T08:00:22Z","timestamp":1502697622000},"page":"90-93","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["\u25bc Eluxadoline for IBS-D"],"prefix":"10.1136","volume":"55","member":"239","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"key":"2026093012001266000_55.8.90.1","unstructured":"Rome Foundation , 2016. What\u2019s new for Rome IV [online]. Available: http:\/\/theromefoundation.org\/rome-iv\/whats-new-for-rome-iv\/ [Accessed 19 July 2017 ]."},{"key":"2026093012001266000_55.8.90.2","unstructured":"European Medicines Agency , 2016. Assessment report: Truberzi [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004098\/WC500213370.pdf [Accessed 19 July 2017 ]"},{"key":"2026093012001266000_55.8.90.3","unstructured":"Northern Treatment Advisory Group , 2016. Eluxadoline for treatment of diarrhoea-dominant irritable bowel syndrome [online]. Available: http:\/\/ntag.nhs.uk\/docs\/app\/Eluxadoline%20NTAG%20appraisal%20report%20for%20web.pdf [Accessed 19 July 2017 ]."},{"key":"2026093012001266000_55.8.90.4","unstructured":"Truberzi 75 mg film-coated tablets and 100 mg flm-coated tablets . Summary of product characteristics, EU. Allergan Pharmaceuticals International Limited, January 2017."},{"key":"2026093012001266000_55.8.90.5","unstructured":"National Institute for Health and Care Excellence , 2017. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care [online]. Available: https:\/\/www.nice.org.uk\/guidance\/cg61 [Accessed 19 July 2017 ]."},{"key":"2026093012001266000_55.8.90.6","unstructured":"National Institute for Health and Care Excellence , 2015. Suspected cancer: recognition and referral [online]. Available: https:\/\/www.nice.org.uk\/guidance\/ng12\/resources\/suspected-cancer-recognition-and-referral-pdf-1837268071621 [Accessed 19 July 2017 ]."},{"key":"2026093012001266000_55.8.90.7","unstructured":"National Institute for Health Research , 2014. Eluxadoline for irritable bowel syndrome (diarrhoea-predominant) \u2013 first line [online]. Available: http:\/\/www.io.nihr.ac.uk\/topics\/eluxadoline-for-irritable-bowel-syndrome-diarrhoea-predominant-first-line\/ [Accessed 19 July 2017 ]."},{"key":"2026093012001266000_55.8.90.8","first-page":"CD006442","article-title":"Psychological treatments for the management of irritable bowel syndrome","volume":"1","author":"Zijdenbos","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2026093012001266000_55.8.90.9","first-page":"CD003460","article-title":"Bulking ag-ents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome","volume":"8","author":"Ruepert","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026093012001266000_55.8.90.10","unstructured":"Colofac Tablets 135mg . Summary of product characteristics, UK. Mylan Products Ltd, August 2016."},{"key":"2026093012001266000_55.8.90.11","unstructured":"National Collaborating Centre for Nursing and Supportive Care , 2017. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care [online]. Available: https:\/\/www.nice.org.uk\/guidance\/cg61\/evidence\/full-guidance-pdf-196701661 [Accessed 19 July 2017 ]."},{"key":"2026093012001266000_55.8.90.12","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.542"},{"key":"2026093012001266000_55.8.90.13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MED.0000000000000302","article-title":"New treatment options for irritable bowel syndrome with predominant diarrhea","volume":"24","author":"Weber","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026093012001266000_55.8.90.14","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.442"},{"key":"2026093012001266000_55.8.90.15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/phar.1712","article-title":"Update on the management of diarrhea-predominant irritable bowel syndrome: focus on rifaximin and eluxadoline","volume":"36","author":"Rivkin","year":"2016","journal-title":"Pharmacother"},{"key":"2026093012001266000_55.8.90.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505180"},{"key":"2026093012001266000_55.8.90.17","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/apt.14031","article-title":"Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies","volume":"45","author":"Chey","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026093012001266000_55.8.90.18","first-page":"771","article-title":"Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome","volume":"12","author":"Sobolewska-W\u0142odarczyk","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"2026093012001266000_55.8.90.19","unstructured":"National Institute for Health and Care Excellence , 2017. Irritable bowel syndrome (diarrhoea) - eluxadoline (ID870) [online]. Available: https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10031 [Accessed 19 July 2017 ]."},{"key":"2026093012001266000_55.8.90.20","unstructured":"U.S. Food and Drug Administration , 2015. FDA approved drug products [online]. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=206940 [Accessed 19 July 2017 ]."},{"key":"2026093012001266000_55.8.90.21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/2327-6924.12387","article-title":"Diarrhea-predominant irritable bowel syndrome: diagnosis, etiology, and new treatment considerations","volume":"28","author":"Lacy","year":"2016","journal-title":"J Am Assoc Nurse Pract"},{"key":"2026093012001266000_55.8.90.22","unstructured":"U.S. Food and Drug Administration , 2017. FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder [online]. Available: https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM546542.pdf [Accessed 19 July 2017 ]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2017.8.0514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:00:34Z","timestamp":1790794834000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2017.8.0514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,14]]},"published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1136\/dtb.2017.8.0514"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2017.8.0514","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}